Roche Holding Ag Stock News

Swiss drugmaker Roche's first quarter sales rose 10%, driven by drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia, and on strong U.S. demand for rapid COVID-19

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S

Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint

Roche is "losing money in Russia", Chief Executive Severin Schwan said in an interview published on Tuesday, but remains committed to providing medication to patients there.

Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American A

The stock price of Roche's ADR has seen a fall of 7% year-to-date, while it's up 3.5% in a month. Roche's revenue grew 13% y-o-y to $72.4 billion in 2021, aided by Covid-19 diagnostics tests and Ronap

Roche'' (RHHBY) (RHHBF) Genentech reported new long term data for for Evrysdi (risdiplam) in spinal muscular atrophy ((SMA)), an inherited disorder characterized by loss of nerve…

Oral presentation on preclinical data demonstrates Prothena''s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer''s, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and to neutralize tau Preclinical data from poster presentation demonstrates that Prothena''s tandem C-terminal α-synuclein vaccine, for the potential treatment and prevention of Parkinson''s, produces robust binding to pathogenic α-synuclein and inhibition of uptake of soluble α-synuclein aggregates into cells Oral presentation by partner Roche on the Phase 2 PASADENA study of prasinezumab, an α-synuclein antibody being developed for the treatment of Parkinson''s, further supports a potential effect on delaying motor progression in patients Prothena leadership will participate in and sponsor two AD/PD 2022 Forum Discussions: Amyloid-Removing Therapies and Anti-Tau Approaches In Clinical Trials AD/PD 2022 honors the legacy of late Prothena Co-founder and CEO, Dale Schenk Ph.D., celebrating his hallmark discoveries in the biology and advancement of therapeutics for Alzheimer''s DUBLIN, Ireland, March 16, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, presented new preclinical data from both its dual Aβ/tau vaccine for the potential treatment and prevention of Alzheimer''s disease (AD) and from its tandem C-terminal α-synuclein vaccine programs for the potential treatment and prevention of Parkinson''s disease (PD) and related synucleinopathies.

Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same period Part 2 of SUNFISH showed Evrysdi demonstrated a marked improvement in, or stabilisation of, motor function after two years compared to an untreated external control group Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babies More than 5,000 patients have been treated with Evrysdi to date, from newborns to people over 60 years of age Basel, 16 March 2022 - Roche ((SIX: RO, ROG, OTCQX: RHHBY ) today announced new data for Evrysdi® (risdiplam) in spinal muscular atrophy (SMA). Presentations included new three-year data from the SUNFISH study which further confirmed the long-term efficacy and safety of Evrysdi in a broad population of people aged 2-25 years with Type 2 or Type 3 SMA.

Biogen Inc (NASDAQ: BIIB ) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies. The first patient treated in the ASCEND study is evaluating the higher dose nusinersen in children, teens, and adults previously treated with Roche Holdings AG''s (OTC: RHHBY ) Evrysdi (risdiplam). ASCEND aims to Full story available on Benzinga.com

MANILA — The Philippines has approved the emergency use of Paxlovid, Pfizer’s PFE.N COVID-19 drug, the country’s food and drug agency said on Friday. It is the third COVID-19 drug approved by the agency for emergency use, after Roche’s ROG.S antibody cocktail and Merck & Co Inc’s MRK.N treatment pill. Paxlovid can be used to treat […] The post FDA approves emergency use of Pfizer’s COVID-19 drug Paxlovid appeared first on Interaksyon .

MANILA: The Philippines has approved the emergency use of Paxlovid, Pfizer’s COVID-19 drug, the country’s food and drug agency said on Friday. It is the third COVID-19 drug approved by the agency for emergency use, after Roche’s antibody cocktail and Merck & Co Inc’s treatment pill. Pfizer begins COVID pill study in high-risk children aged 6-17 Paxlovid can be used to treat adult patients who do not require supplemental oxygen and who are at increased risk for severe infection, the agency said.

Callable Multi Barrier Reverse Convertible auf ABB , Nestlé, Roche, Zurich Insurance / Adecco, Holcim, Swiss Re / Nestlé, Novartis, Roche, Swiss Life / Alphabet, Meta Platforms, Walt Disney

Basel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its growing neuromuscular portfolio will be presented at the Muscular Dystrophy Association (MDA) Clinical